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REVIEW
Background and objectives: Migraine is a highly prevalent neurological disorder with
multiple peripheral and central mechanisms. Targeting a single mechanism for treating
individual attacks as well as for performing the prophylaxis has been shown to be only partially
effective. Recently, the role of combining agents for acute migraine treatment has gained
attention and the combination of a triptan plus a non-steroidal anti-inflammatory drug (NSAID)
has demonstrated better efficacy. This review focuses on the fundamentals of treating migraine
attacks with two or more agents, and emphasizes the characteristics of the recently approved
fixed combination sumatriptan–naproxen.
Methods: A PubMed search using the terms “migraine”, “treatment”, “acute”, “triptans”,
“non-steroidal anti-inflammatory drugs”, “sumatriptan”, “naproxen”, and “combination” was
used. In addition, abstracts presented in the major meetings of the American Headache and
the International Headache Societies along with the American Academy of Neurology were
also evaluated.
Results: Although most of the few studies encountered were not controlled, there is a clear
trend for better efficacy in combining triptans with NSAID. Additionally, the results of two
recent large and controlled studies using fixed combinations of sumatriptan (50 mg and 85 mg)
with 500 mg naproxen sodium confirm the initial observations of the clear superiority of this
combination over the use of each agent alone. The differences in the endpoints 24-hour pain-
relief response as well as pain-free and pain-relief parameters at 2-hour time-point are the
most noticeable efficacy measures. Tolerability was not different between studied drugs.
Conclusions: Combining triptans with NSAID and other agents for the acute treatment of
migraine suggests better outcome efficacy measures than the use of single agents. The fixed
combination of sumatriptan and naproxen sodium offers improved 2-hour and 24-hour benefits
over monotherapy with each one these options. Recently issued FDA approval for marketing
the combination (sumatriptan 50 mg–naproxen 500 mg) emphasizes the usefulness and safety
of this new treatment for migraine attacks.
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Introduction and background
Migraine is a highly prevalent disorder manifesting clinically as headache attacks of
moderate to severe or severe intensity. Migraine attacks generally induce a great
deal of disability among its sufferers,
, resulting in considerable economic and social
losses (Stewart et al 1994, 1996; Rasmussen 1995; Lipton and Stewart 1997; ICHD-
II 2004).
The pathophysiology of migraine is multifaceted and complex. It is a primary
headache disorder with a clear genetic basis, but during the intermittent attacks of
headache, primary neural events result in the dilatation of meningeal blood vessels,
which in turn results in pain, further nerve activation, and inflammation (Lipton and
Stewart 1997). Migraine is currently considered a neurovascular headache, where
the pain is interpreted as a combination of altered perception (due to peripheral or
central sensitization) of stimuli that are usually not painful, as well as the activation
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of a neurovascular dilator mechanism in the first
(ophthalmic) and second divisions of the trigeminal nerve.
These events are probably initiated by the phenomenon of
cortical spreading depression, at least in migraine with aura,
but it may also occur in migraine without aura. It is important
to emphasize that the pathophysiology of migraine involves
multiple compartments of the nervous system, as well as
multiple neurotransmitters (Goadsby et al 2002).
The objective of acute migraine therapy is to restore the
patient to normal function by rapidly and consistently
alleviating the head pain and the associated symptoms of
nausea, vomiting, and sensory phobias without side-effects
and recurrence of the attack within 24 hours (Tfelt-Hansen
and Welch 2000). Several drug options and different
formulations are available to treat migraine acutely. The
choice of a specific medication type depends on individual
characteristics such as headache intensity, speed of onset of
action, presence of associated symptoms, the degree of
incapacitation, and the patient’s response (Tfelt-Hansen and
Lipton 1993; Dodick 2001). In addition, the preference of
the patients as well as the treating physicians is to achieve
rapid pain-free status (Lipton et al 2002). Unfortunately,
the current acute treatment for migraine is not effective in
all patients. Using available options, despite the selectivity
for the serotonergic system obtained with the triptans, a
probable ceiling effect of around 70% probably exists.
Monotherapy, especially orally, does not result in rapid,
consistent, and complete relief of migraine in all patients
(Peroutka 1998). Additionally, the aura phase of patients
with migraine with aura cannot be effectively treated, side-
effects may occur in up to 89% of the patients, and up to
31% of those taking sumatriptan, for example, discontinue
use due to lack of efficacy, headache recurrence, cost, and/
or side-effects (Bates et al 1994; Dahlof 1995; Visser et al
1996a, 1996b). We have noticed this in clinical practice
during the first half of the 1990s. At that time, dealing
exclusively with headache patients, we have seen many
patients who took the recently launched sumatriptan (in
Brazil, it was released during the end of 1992) who were
dissatisfied with the results and the costs of the new
medication. Most have tried the subcutaneous formulation
and repeatedly complained about recurrence and side-
effects. With the oral formulations, the lack of a pain-free
status was the frequently reported limitation. From the end
of 1994, we started to combine sumatriptan with a non-
steroidal anti-inflammatory medication in order to observe
the behavior of the headache with regard to efficacy and
sustained pain relief. Surprisingly, the commercially driven
aim of others patenting our idea has impeded further studies
completely. The aim of this review is to discuss the
progressively changing approach of treating migraine
attacks with combination therapy in addition to recent
evidence of the superiority presented by the fixed
combination sumatriptan–naproxen over the use of each of
both agents alone.
Search methodology
A bibliographic search was conducted of manuscripts
indexed on PubMed, written in English or with an abstract
in English that allowed abstraction of relevant data. The
keywords we chose were “migraine”, “treatment”, “acute”,
“triptans”, “non-steroidal anti-inflammatory drugs”,
“sumatriptan”, “naproxen”, and “combination”. We used an
exploded search strategy for combining the keywords.
Letters to the editor were excluded but abstracts presented
on major meetings carried out by the American Headache
Society and the International Headache Society during the
last 5 years were used for evaluation. Data presented on the
American Academy of Neurology meetings were also
reviewed. We screened the results to find clinical trials on
fixed drug combinations for the acute treatment of migraine.
Results
The experience supporting the role of the synergistic effect
of drug combinations in the acute treatment of migraine is
not new. Lance (1981) recommended the administration of
metoclopramide before the intake of an ergot derivative in
order to allow a faster gastric absorption, which is impaired
during a migraine attack. Wilkinson (1983) reported that
61% of her patients had total or significant relief of migraine
following a regimen that included a dopamine antagonist, a
simple analgesic, and an attempt to sleep. In the remaining
patients, an ergot preparation was added and resulted in a
total efficacy rate of 91%.
Triptans have been compared with combinations of non-
specific agents for migraine. Two studies demonstrated the
effectiveness of combination therapy for migraine attacks
(OSAM 1992; Tfelt-Hansen et al 1995). In one randomized
controlled study, 100 mg sumatriptan was compared with
900 mg acetyl salicylic acid (ASA) plus 10 mg
metoclopramide (MCP). Patients were instructed to wait
until moderate to severe pain to treat, and then treat three
attacks. The primary endpoint was pain relief (also called
headache response or headache relief; moderate severe pain
reduced to mild or no pain at 2 hours after treating moderateNeuropsychiatric Disease and Treatment 2006:2(3) 295
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to severe pain) at 2 hours. For the first attack, headache
relief occurred in 45% of the patients taking ASA/MCP
compared with 56% of those taking sumatriptan (not
statistically significant). In the second and third attacks,
sumatriptan 100 mg was superior to ASA/MCP. Recurrence
over 48 hours was higher with sumatriptan than ASA/MCP
(42% vs 33%). No information on 4-hour relief or pain-
free results were published, but 6-hour complete relief
(migraine free) was higher for sumatriptan in all three attacks
(OSAM 1992). The second study was a comparison of lysine
acetylsalicylic acid 900 mg (LASA) plus 10 mg MCP vs
sumatriptan 100 mg over two attacks. The primary endpoint
was headache relief at 2 hours after treating moderate to
severe pain in the first attack. There was no significant
difference between the LASA/MCP and the sumatriptan,
this time for either attack. Migraine free at 2 hours and
recurrence over 24 hours were statistically the same for
LASA/MCP and sumatriptan (Tfelt-Hansen et al 1995).
These studies emphasize that a combination of two different
non-specific pharmacological classes may be as effective
as the use of specific selective agents for migraine treatment.
 There have been demonstrations that combining a
triptan plus a non-steroidal anti-inflammatory drug (NSAID)
reduces recurrence in clinical practice and may be more
efficacious. In an open study, 240 moderate or severe
migraine attacks were treated with 100  mg sumatriptan and
200  mg of tolfenamic acid or sumatriptan alone. Recurrence
of any pain (primary endpoint – even mild pain was
considered) was 62.5% for sumatriptan and 23.8% for
combination (Krymchantowski et al 1999). In another study
with a placebo-controlled design, the combination of 100 mg
sumatriptan and 550 mg naproxen sodium significantly
reduced recurrence from 59% (sumatriptan and placebo) to
25.5% (sumatriptan plus naproxen) (Krymchantowski
2000).
The efficacy and tolerability of the combination
sumatriptan 50 mg (encapsulated) and naproxen sodium
500 mg administered concurrently was also evaluated in a
recent multicenter, randomized, double-blind, double-
dummy, placebo-controlled, four-arm study (Smith et al
2005). In this study, 972 patients treated a single moderate
or severe migraine attack with placebo, naproxen sodium
500 mg, sumatriptan 50 mg, or a combination of both active
drugs. Twenty-four-hour pain relief response was the
primary endpoint, which was achieved by 46% of the
combination-treated group compared with 26% of the
sumatriptan-treated patients, 25% of the naproxen-treated
patients, and 17% of the placebo-treated patients (p<0.001
for all comparators). The other endpoints, 2-hour headache
response, 2-hour pain free response, and the improvement
of associated symptoms at 2 hours also favored the
combination of sumatriptan and naproxen sodium
significantly (p<0.001). For 2-hour headache response the
combination group revealed favorable response 65%,
whereas 49%, 46%, and 27% of the sumatriptan-, naproxen
sodium-, and placebo-treated patients, respectively, were
better. However, tolerability was similar among all groups,
which emphasizes the better efficacy of this combination
without higher occurrence of adverse events.
The results of two identical randomized, double-blind,
placebo-controlled and parallel-group studies carried out
in various centers treating a single moderate–severe
migraine attack with sumatriptan (85 mg) plus naproxen
sodium (500 mg), sumatriptan 85 mg, naproxen sodium
500mg, or placebo were recently reported (Brandes et al
2005). In the first study, 1470 patients were enrolled and
the combination revealed significant superiority over
placebo in pain-free and pain-relief dates at 2 hours
(p<0.001). For sustained pain-free response, the
combination of sumatriptan and naproxen sodium was also
superior to sumatriptan, naproxen sodium, and placebo
(p<0.001). The adverse events were similar among treated
groups but no further details were presented. The second
study is underway and enrolled 1441 patients.
Rizatriptan was also studied in combination with
rofecoxib in two trials (Krymchantowski and Barbosa 2002;
Krymchantowski et al 2004). In the first trial, absence of
headache at 1 hour was seen in 25% of patients for rizatriptan
vs 42% for combination (p=0.082); at 2 hours the figures
were 60% and 76% (not significant). Recurrence of any pain
was observed in 53% of subjects receiving rizatriptan vs
20% in the combination of group (Krymchantowski and
Barbosa 2002).
Recently, a prospective, randomized, open study with
regular patients of a tertiary center assessed randomized
subjects to treat six consecutive attacks with rizatriptan (RI),
rizatriptan and tolfenamic acid (RI+TA), or rizatriptan plus
rofecoxib (RI+RO) in counterbalanced order
(Krymchantowski et al 2004). A total of 184 attacks was
treated. The pain-free rates at 1 hour were: RI: 15.5%;
RI+RO: 22.6%; RI+TA: 20.3% (not significant). Pain-free
rates at 2 hours were: RI: 37.9%; RI+RO: 62.9%, and
RI+TA: 40.6% (p=0.008 for RI vs RI+RO; p=0.007 for
RI+RO vs RI+TA, not significant for RI vs RI+TA). At 4
hours, pain-free rates were: RI: 69%; RI+RO: 82.3%;
RI+TA: 78.1% (not significant for all comparisons). TheNeuropsychiatric Disease and Treatment 2006:2(3) 296
Krymchantowski
combination of RI+RO was superior to RI and to RI+TA
for the absence of nausea and photophobia at 4 hours.
Recurrence (after being pain-free at 2 hours) was observed
in 50% of patients treated with RI, in 15.4% of those treated
with RI+RO, and in 7.7% of those treated with RI+TA
(Krymchantowski et al 2004).
Migraine attacks already with developed cutaneous
allodynia may also benefit from combination therapy.
Burstein et al (2005) tested sumatriptan injection and the
COX1/COX2 inhibitor ketorolac to block ongoing
sensitization in 23 patients who were treated with 6 mg SC
sumatriptan 4 hours after the onset of migraine and with
ketorolac 2 hours later (two IV boluses, 15 mg each, 10
minutes apart) (Burstein et al 2005). The patients remained
allodynic after the sumatriptan injection but the
administration of ketorolac 2 hours later rendered 74% of
the patients both allodynia-free and pain-free within 1 hour.
The authors suggested the possibility that the therapeutic
action of COX1/COX2 inhibition was facilitated, to a certain
degree, by the preceding action of sumatriptan (Burstein et
al 2005).
The combination of a triptan (rizatriptan) and the
peripheral opioid agonist trimebutine maleate was also
superior than rizatriptan alone. The addition of this exclusive
opioid receptor agonist acting at the Meissner and Auerbach
mioenteric plexus to 10 mg of rizatriptan rendered 70.1%
of pain-free status compared with 29.9% of the attacks
treated with rizatriptan (p<0.0001) in the same patients
through a randomized, cross-over, placebo-controlled trial.
In this study, nausea and photophobia were also significantly
better with the combination at 1- and 2-hour timepoints
compared with rizatriptan alone (Krymchantowski et al
2005).
Conclusions
Several areas of the central nervous system and vascular
system, together with different mediators, are involved in
migraine. As current treatments are not effective in a sizeable
portion of the migraine sufferers, combining different classes
of pharmacological agents is an attractive strategy for some
patients. Additionally, most headache specialists consistently
mention the fact that some of their patients use two, three,
or eventually more pharmacological agents either to achieve
reduction in headache frequency as well as to treat more
effectively the intermittent attacks. This has also been our
experience over the years in treating headache patients,
mostly in tertiary centers. However, as described above, only
a few studies deal with this issue, mostly uncontrolled and
therefore unreliable, although clear trends for better efficacy
and 24-hour outcome measures are suggested.
On the other hand, the specific combination of
sumatriptan and naproxen sodium was studied in
randomized, controlled trials with proven efficacy and
superiority over the use of each substance alone in various
dosages. Initially we have demonstrated that two groups of
13 patients, who were recruited from a regular population
under treatment in a tertiary center, had treated 39 moderate–
severe attacks combining sumatriptan (100 mg) with placebo
or with naproxen sodium (550 mg) in a double-blind design.
The recurrence rate was significantly lower in the
combination group compared with the placebo group (25.5%
vs 59%, p<0.001). These patients had treated migraine
attacks before with sumatriptan and with sumatriptan plus
naproxen in an open-label fashion, revealing the clear trend
for recurrence reduction with the combination. The recent
studies with more appropriate methodology and larger
populations of subjects confirmed our initial observations
demonstrating that the combined use of sumatriptan (either
50 mg or 85 mg) and naproxen sodium (500 mg) do provide
superior sustained response rates without increasing adverse
events. Perhaps the use of other triptans with different
NSAID or gastrokinetic drugs, as suggested in the studies
described, do also provide better sustained response
measures (sustained pain-free, sustained headache response,
incidence of recurrence) and 2-hour pain-free or pain-relief
measures. It is reasonable to suggest that since monotherapy
with triptans or with NSAID commonly provide 2-hour
response rates between 50% and 80%, and only half of such
patients achieve a sustained response by 24 hours, the use
of acute treatments with longer durations of efficacy are
needed (Ferrari et al 2002; Goadsby et al 2002; Smith et al
2005). We all hope that future studies will provide better
evidence of the advantages of using combination therapies
in all parameters related to the treatment outcome, therefore
promoting better efficacy, good tolerability, and less
suffering, as hoped for by millions of migraineurs.
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